Introduction
============

The *BORIS/CTCFL* (Brother of the Regulator of Imprinted Sites/CTCF-like protein) gene is classified as a member of the cancer-testis antigen (CTA) family; it is expressed in the testis during spermatogenesis,^[@bib1],\ [@bib2]^ as well as in multiple cancers, including uterine (endometrial), breast, lung and gastric cancers.^[@bib3],\ [@bib4],\ [@bib5],\ [@bib6]^ High levels of the BORIS protein in the leukocytes of patients with breast cancer were detected, which suggests that *BORIS* can be used as a valuable marker.^[@bib7]^ Moreover, a CpG island in the promoter region of *BORIS* is known to be a key factor regulating gene expression,^[@bib4],\ [@bib8]^ and *BORIS* expression in human cancer cells has been proposed to lead to epigenetic deregulation. Overexpression of *BORIS* has been correlated with the hypomethylation of its promoter in prostate and ovarian cancers in several reports,^[@bib9],\ [@bib10]^ and partial demethylation of the *BORIS* promoter has been detected in ovarian,^[@bib11]^ colon^[@bib11]^ and lung cancer^[@bib8]^ and in leukemic cell lines.^[@bib11]^ However, in our previous study, no correlation between methylation status and *BORIS* gene expression in gastric cancer tissues was detected.^[@bib6]^

To elucidate the regulation of *BORIS* during tumorigenesis, in a previous study, we characterized the entire genomic region of the *BORIS* locus including the promoter region in gastric cancer cells.^[@bib12]^ A CpG island (−1096 to −762 from the first ATG) and two minisatellites (variable number of tandem repeats; *BORIS*-MS1 and *BORIS*-MS2) were identified through the characterization of the genomic DNA sequence upstream of the gene-coding region.^[@bib12]^ In this study, we assessed the expression and methylation status of the *BORIS* gene in lung cancer tissues and re-analyzed the regulatory elements, that is, the CpG island and two minisatellites, in its promoter region to determine whether these elements are necessary for expression of a reporter gene in lung cancer cells. In addition, we described two well-positioned elements that contained the binding sequences for GATA-1^[@bib13]^ and the CCAAT box.^[@bib14]^

Lung cancer is the most commonly diagnosed cancer and the leading cause of death in males. In addition, it is the fourth most common cancer in females worldwide, based on GLOBOCAN 2008 estimates,^[@bib15]^ and it is a major public health problem in Korea. Because some minisatellite alleles are associated with human diseases,^[@bib16],\ [@bib17]^ we investigated the relationship between cancer predisposition and minisatellite variants in *BORIS*^[@bib6],\ [@bib12]^ and revealed increased susceptibility in young patients with breast cancer containing short rare minisatellite alleles of *BORIS*-MS2. To determine whether allelic variation in *BORIS* minisatellites influences susceptibility to lung cancer, a case--control study was performed using a PCR-based method. Here, we report that rare allelic variants of *BORIS*-MS2 are correlated with lung cancer susceptibility in a Korean population. In addition, to assess whether this minisatellite region has a role in gene regulation, the transcriptional levels of a reporter gene linked to the minisatellites and driven by the *BORIS* promoter in lung cell lines were examined.

Materials and methods
=====================

Study population and genotyping assays for *BORIS-MS2*
------------------------------------------------------

To examine the minisatellite polymorphisms in *BORIS-*MS2, a case--control study was performed with 590 cancer-free controls and 206 lung cancer cases. The controls and cases had similar characteristics regarding sex and age (control average age, 60.5 years, range 30--83 years; patient average age, 63.0 years, range 32--82 years) ([Table 1](#tbl1){ref-type="table"}). Controls were selected from the Department of Preventive Medicine and Internal Medicine at Dong-A University hospitals between 1997 and 2004 (Busan, Korea).^[@bib12]^ The control group, with no personal history of cancer or current cancer, was recruited and completed an interview. The biospecimens from lung cancer patients in this study were provided by the Chungbuk National University Hospital, a member of the National Biobank of Korea, which is supported by the Ministry of Health, Welfare and Family Affairs and Dong-A University Hospital in Busan, Korea. All samples from the National Biobank of Korea were obtained with informed consent and institutional review board-approved protocols. The Committee of Bioethics of Dong-A University approved the procedure and design of this study (\#IRB-06-10-02 & IRB-07-10-7; Busan, Korea).

For genotyping, genomic DNA was isolated from peripheral leukocytes, which were isolated from 400 μl of whole blood using a Blood and Cell Culture DNA Mini Kit (Qiagen, Valencia, CA, USA). The genotyping assay of the minisatellite polymorphism was described previously^[@bib12]^ with the PCR primer pair 5′-CTTGGGAGACCTGGGGGATGAATAG-3′ (forward) and 5′-GCACCCCATTCCCCATCCTC-3′ (reverse) for *BORIS*-MS2. The PCR products were separated on a 1.2% agarose gel at 80 V for 4 h and then stained with ethidium bromide.

RNA isolation and reverse transcription
---------------------------------------

Total RNA was isolated from tissues using TRIzol reagent (Invitrogen, Carlsbad, CA, USA) according to the manufacturer\'s instructions. The Qiagen RNeasy Mini kit (Qiagen) was used for isolation of total RNA from cell lines and lung cancer tissue specimens. For the reverse transcription reaction, a mixture of total RNA (3 μg), an oligo(dT)~20~ (50 n[M]{.smallcaps}) and 10 m[M]{.smallcaps} dNTP were incubated at 65 °C for 5 min. A mixture of 1 × RT buffer, 25 n[M]{.smallcaps} MgCl~2~, 0.1 [M]{.smallcaps} DTT and RNaseOUT were incubated at 42 °C for 2 min. After incubation, Invitrogen SuperScript III (200 U μl^−1^) was added. This mixture was then incubated at 42 °C for 50 min followed by 70 °C for 15 min. RNase H (2 U μl^−1^) was then added, and the sample was incubated at 37 °C for 20 min in a 9700 Thermocycler (Perkin-Elmer, Waltham, MA, USA) as described previously.^[@bib12]^

Bisulfate sequencing of the *BORIS* promoter regions
----------------------------------------------------

Genomic DNA was subjected to bisulfite modification using the EZ DNA Methylation-Gold Kit (Zymo Research, Irrine, CA, USA). Each sequence was amplified using G-Taq polymerase (Cosmo Genetech, Seoul, Korea) as previously described.^[@bib6]^ PCR fragments were gel extracted using a Gel Extraction kit (Qiagen) and ligated into the Mighty TA cloning vector (TaKaRa, Kusatsu, Shiga, Japan). Following transformation, plasmids from individual bacterial colonies were isolated and sequenced. Using bisulfate sequencing, the methylation status of the *BORIS* promoter region was determined and represented as follows: open circles indicate non-methylated CpG and filled circles indicate methylated CpG ([Figure 1](#fig1){ref-type="fig"}).

Plasmid construction
--------------------

To generate the luciferase reporter vectors with various fragments of the *BORIS* 5′-promoter region, fragments were amplified from a bacterial artificial chromosome clone ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) containing the *BORIS* genomic sequence by PCR and inserted into the *Kpn*I/*Nhe*I sites of the luciferase reporter vector pGL3-Basic (Promega, Madison, WI, USA). The primers and the plasmids in this study are listed in [Supplementary Table S1](#sup1){ref-type="supplementary-material"}. To characterize the effect of *BORIS*-MS2 on BORIS expression, part of the *BORIS* promoter p700 (−1108 to −425) was cloned and introduced into the *Bgl*II/*Hin*dIII sites of the luciferase reporter vector pGL3-Basic to generate the p700 fragment ([Figure 2](#fig2){ref-type="fig"}). Mutated constructs (GATA-1Δ\#1, GATA-1Δ\#2 and CCAATΔ) were prepared by substitution of the GATA-1 site and CCAAT box in the p700 construct as shown in [Figure 3](#fig3){ref-type="fig"}. Two common (TR14 and TR15) alleles and five rare alleles (TR10, TR13, TR16, TR17 and TR18) were amplified from genomic DNA derived from controls and cases and inserted into the *Kpn*I/*Bgl*II sites of the p700 fragment to generate the reporter plasmids p700+TR10, p700+TR13, p700+TR14, p700+TR15, p700+TR16, p700+TR17 and p700+TR18 ([Figure 4](#fig4){ref-type="fig"}). All constructs were confirmed by DNA sequencing.

Cells and luciferase assays
---------------------------

The following human cell lines were tested for the effect of *BORIS*-MS2 on *BORIS* expression: 293T/HEK293T (human embryonic kidney cell line obtained from the Korean Cell Line Bank (KCLB, Seoul, Korea), H1299 (lung cancer cell line from the American Type Culture Collection (ATCC, Manassas, VA, USA) and MDA-MB-231 (breast cancer cell line from KCLB). For the luciferase assay, cells (1 × 10^5^) were seeded in 12-well plates, cultured overnight and transfected with the *BORIS* promoter-luciferase plasmids (0.5 μg per well) using the FuGENE6 transfection reagent (Roche Diagnostics, Indianapolis, IN, USA) at a ratio of DNA/FuGENE6 of 1:3. Analysis of the cells was performed using a dual-luciferase reporter assay system (Promega) 48 h after completion of the transfection procedure. Firefly luciferase activities were normalized to *Renilla* luciferase activity, and activity was expressed in relative luciferase units to reflect the promoter activity. Triplicate transfections of each construct were tested for each experiment, and the final results were calculated from four independent experiments.

Statistical analysis
--------------------

Regression analyses were carried out to determine the odds ratios (ORs) of association between the control and case groups. ORs were predicted using the natural logarithm and its s.e. Where relevant, a *χ*^2^-test was performed with one degree of freedom for statistical significance. Differences were regarded as significant with confidence intervals (CIs) of 95%. All tests were two-sided, with *P*\<0.05 considered statistically significant. Statistical analyses were performed using MS Excel with CHITEST and R statistical software (v2.5.1, [www.r-project.org](http://www.r-project.org)) with *χ*^2^-test for the *χ*^2^-calculation values. The Kaplan--Meier plot was used in the R program version 2.10.0 (<https://www.r-project.org/>).

Results
=======

*BORIS* expression and methylation status in lung cancer tissues
----------------------------------------------------------------

*BORIS* gene expression was examined in 20 cell lines, which included normal fibroblast, osteosarcoma, melanoma, breast cancer, prostate cancer, colon cancer, lung cancer and gastric cancer cell lines from a previous study.^[@bib6]^ Compared with the normal cells, various cancer cells, including osteosarcoma, melanoma, breast cancer, prostate cancer, colon cancer, lung cancer and gastric cancer showed abnormal expression of *BORIS*. Among the lung cancer cell lines (A549, H358, H460, H1299), H1299 cells showed the highest expression.^[@bib6]^ Then, we investigated *BORIS* gene expression in lung tumor tissues ([Figure 1](#fig1){ref-type="fig"}). In 10 lung tumor tissues, the *BORIS* levels were different; the lowest levels were observed in 2 cancer tissues (T2 and T10), moderately increased levels were observed in 4 cancer tissues (T1, T3, T4 and T5) and the highest levels were detected in 4 cancer tissues (T6, T7, T8 and T9) at the same level as the H1299 cancer cell line ([Figure 1a](#fig1){ref-type="fig"}). To analyze the possible relationship between *BORIS* gene activity and epigenetic changes in lung cancer, we assessed DNA methylation levels in these tumor tissues. As previously reported in gastric cancer tissues,^[@bib6]^ methylation (89.1--95.7%) of the *BORIS* promoter region in lung cancer tissues was almost the same despite the different degree of *BORIS* expression ([Figure 1b](#fig1){ref-type="fig"}). The lung cancer cell line H1299 also showed similar levels of methylation (94%), but cells treated with 5-azad-C (1 and 5 μ[M]{.smallcaps}) showed decreased methylation levels (31.7--47%). We next extensively analyzed the *BORIS* promoter region to elucidate the regulation of this gene during tumorigenesis.

Cloning of the 5′-regulatory region of the *BORIS* gene and characterization of transcriptional activities of the promoter
--------------------------------------------------------------------------------------------------------------------------

We cloned the genomic fragment containing the entire *BORIS* gene region ([Supplementary Figure S1](#sup1){ref-type="supplementary-material"}) from human genomic DNA using the TAR cloning method.^[@bib18]^ Two clones containing a \~70-kb genomic fragment were isolated and found to carry the entire *BORIS* gene ([Supplementary Figures S1B and C](#sup1){ref-type="supplementary-material"}). The YAC clone was identified by screening a mini-YAC library with PCR using a set of diagnostic primers ([Supplementary Table S1](#sup1){ref-type="supplementary-material"}). The YAC includes the *BORIS*-coding region, the \~30 kb 5′ upstream region and the \~8 kb 3′ flanking regions. TAR cloning of *BORIS* in yeast greatly simplifies PCR amplification of the promoter regions enriched by repeated and CG-rich sequences, which are poorly amplified from human genomic DNA. We constructed the various reporter vectors (see Materials and Methods, [Supplementary Table S1](#sup1){ref-type="supplementary-material"},[Figures 2](#fig2){ref-type="fig"},[3](#fig3){ref-type="fig"},[4](#fig4){ref-type="fig"}) using this clone (*BORIS* I, [Supplementary Figures S1B and C](#sup1){ref-type="supplementary-material"}),

Transient transfection of 293T cells with the cloned −2909/+5 genomic fragment (p2914) using the luciferase reporter construct resulted in a significant (*P*\<0.001) increase in promoter activity, which was \>18-fold greater than the activity observed with the pGL3-Basic vector ([Figure 2a](#fig2){ref-type="fig"}). In contrast, a larger 5115 bp genomic fragment (p5115; −5110/+5) of the *BORIS* 5′-regulatory region cloned into the pGL3-Basic plasmid and transfected in 293T cells did not show any promoter activity ([Figure 2a](#fig2){ref-type="fig"}).

To determine the core *BORIS* promoter, we performed 5′-deletion analysis to determine the minimal region required for *BORIS* promoter activity ([Figure 2b](#fig2){ref-type="fig"}). The promoter activity of each of the deletion constructs was assessed by measuring luciferase activities in transiently transfected 293T cells. The results showed that luciferase activity from the shorter 700-bp promoter fragment (−1108/−425, p700) had approximately threefold greater activity than the full-length fragment (p2914); this p700 vector contained the CpG and GATA-1 regions. This observation suggests the possible existence of a strong suppressor element between −2909 and −1108 nt of the *BORIS* 5′-regulatory region, that is, the minisatellite region ([Figure 2b](#fig2){ref-type="fig"}).

A previous study^[@bib11]^ reported three transcription start sites in the BORIS sequence---1447, 899 and 658 bp upstream of the first ATG codon. This observation suggests the presence of three alternative promoter regions that may have cell type-specific activity. We constructed three expression cassettes (PrA, PrB and PrC) containing the predicted promoters^[@bib11]^ and compared levels of luciferase expression in HEC293 cells ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}). The p700 vector containing the CpG and GATA-1 regions showed the highest promoter activity, which was over 60-fold greater than the activity observed with the pGL3-Basic vector ([Supplementary Figure S2](#sup1){ref-type="supplementary-material"}).

To obtain information on putative regulatory sites in the p700 promoter region of the *BORIS* gene, we analyzed the DNA fragment (−1108/−425). As shown in [Figure 2](#fig2){ref-type="fig"}, a deletion of 23 bp from the 3′-end of the p700 vector (vector p678) resulted in a dramatic reduction in promoter activity. The deleted region (−447/−425 region, [Figure 2](#fig2){ref-type="fig"}) includes the GATA-1-binding site and the CCAAT box.^[@bib11]^ To assess the involvement of these putative regulatory sites in regulating the promoter activity of the *BORIS* gene, we introduced specific mutations in the core sequences of these sites and examined the effect of these mutations on promoter activity ([Figure 3a](#fig3){ref-type="fig"}). The results show that mutating these elements led to a significant (*P*\<0.01) reduction in promoter activity compared with the p700 promoter ([Figure 3b](#fig3){ref-type="fig"}). These results suggest that the region including the GATA-1 site and the CCAAT box has a role in activating *BORIS* expression.

Effect of minisatellites (*BORIS-MS2*) on *BORIS* expression
------------------------------------------------------------

The comparative promoter activities of p2914 and p700 in [Figure 2b](#fig2){ref-type="fig"} suggests the presence of a suppressor element located in the −2909 to −1108 region; this region corresponds to the minisatellites of *BORIS*-MS2. Therefore, we constructed seven different vectors ([Figures 4a](#fig4){ref-type="fig"}; p700+TRs) consisting of the p700 fragment and the *BORIS*-MS2 minisatellites (TR10, TR13, TR14, TR15, TR16, TR17 and TR18), which were genotyped using genomic DNA from lung cancer cases ([Figure 5](#fig5){ref-type="fig"}). For all seven constructs harboring minisatellites, the luciferase activities were significantly reduced in 293T cells compared with the p700 reporter vector (5- to 10-fold reductions) ([Figure 4b](#fig4){ref-type="fig"}). Notably, when the same *BORIS-MS2*-containing constructs were transfected into lung cancer cells (H1299) or breast cancer cells (MDA-MB-231), we observed only a approximately twofold reduction in promoter activity ([Figures 4b and c](#fig4){ref-type="fig"}). This result suggests that the constructs containing the minisatellites showed different promoter activity in normal and cancer cell lines. In addition, we also constructed seven variants of the p2298 vector, which included the p700 promoter region, the region between the p700 promoter and *BORIS*-MS2, and different fragments of *BORIS*-MS2 (10--18 copies of a 56 bp repeat) ([Supplementary Figure S3](#sup1){ref-type="supplementary-material"}). These constructs were also transfected into three different cell lines, and similar results were observed. Therefore, *BORIS*-MS2 minisatellites may have a role in aberrant activation of *BORIS* during carcinogenesis. Next, we investigated a possible link between the minisatellite variants and lung cancer in a Korean population.

Analysis of minisatellite variants in lung cancer patients
----------------------------------------------------------

Several lung cell lines and many lung tumor specimens express high levels of *BORIS*.^[@bib6],\ [@bib8]^ Because *BORIS* is a potential new marker for the detection of lung cancer, we investigated whether *BORIS*-MS2 may correlate with lung cancer development. In a previous study, *BORIS*-MS2 was found to possess genetically variable alleles.^[@bib6],\ [@bib12]^ In this study, we investigated whether these alleles are linked to activation of *BORIS* during tumorigenesis. For this purpose, the frequency of polymorphic *BORIS*-MS2 alleles was compared between controls and patients with lung cancer in a Korean population ([Table 1](#tbl1){ref-type="table"}). This analysis included PCR amplification of the minisatellite from human genomic DNA samples isolated from 590 cancer-free controls and 206 patients with lung cancer ([Table 1](#tbl1){ref-type="table"}). *BORIS*-MS2 had 12 types of haploid patterns in controls ([Figure 5a](#fig5){ref-type="fig"}) and 10 types of haploid patterns in cancer cases ([Figure 5b](#fig5){ref-type="fig"}). [Figure 5c](#fig5){ref-type="fig"} summarizes the frequency of haploid patterns for *BORIS*-MS2 between the controls and the lung cancer groups. Among the identified haploid patterns, the 13/14 genotype of *BORIS*-MS2 (corresponding to 13 copies of the satellite repeat on 1 chromosome and 14 copies of the satellite repeat on another chromosome) was significantly more frequent in cases (2.9%) than in controls (0.5%) (*P*\<0.005), and for the frequency of the allelic distribution ([Table 2](#tbl2){ref-type="table"}) 13 repeated alleles of *BORIS*-MS2 were significantly more frequent in cases than in controls (0.5 vs 1.7%). Analysis of these data revealed a significant association between 13 tandem repeat alleles and the odds for lung cancer (*BORIS*-MS2 and lung cancer OR: 3.38, CI: 1.13--10.12; *P*=0.021).

For further analysis, each *BORIS*-MS2 allele was divided into common or rare alleles (the frequency for rare alleles was \<1%) based on their frequency in the control population.^[@bib12]^ Seven alleles of *BORIS*-MS2 were grouped into 2 common alleles (14 and 15 repeats) and 5 rare alleles (10, 13 16, 17 and 18 repeats) in this study ([Table 3](#tbl3){ref-type="table"}). There was a significant difference in the frequency of rare alleles found in controls and cancer cases (OR: 2.04, CI: 1.02--4.08; *P*=0.039). Specifically, the frequency of rare alleles in female cases with lung cancer showed a statistically significant difference between controls and cases (OR=3.14; *P*=0.047). Furthermore, we divided the rare alleles into short (10 and 13) and long (16, 17 and 18) groups based on their tandem repeat lengths ([Table 4](#tbl4){ref-type="table"}). The analysis of the short rare alleles (10 and 13 repeats) group, comparing controls and cases, also showed an association, with a relative lung cancer OR of 2.37 (*P*=0.049). There was a more significant difference in the frequency of short rare alleles between male controls and male cases (OR=3.86; *P*=0.041) ([Table 4](#tbl4){ref-type="table"}).

We used clinicopathological information obtained in 2009 from the Korea University Anam Hospital in Korea^[@bib19]^ and between 2002 and 2007 from Dong-A University and Chungbuk National University Hospital in Korea ([Supplementary Table S2](#sup1){ref-type="supplementary-material"}). Tumors, nodes and distant metastasis stages were analyzed according to the World Health Organization (WHO) system. Lung tumors were categorized into the appropriate class, and we then assessed the frequency of each class in the entire cancer group and the rare allele group. There was no association between short rare alleles and cancer classification corresponding to stage, T stage, N stage, M stage or cell type.

Discussion
==========

*BORIS* is a CTA gene family member, and its transcription is abnormally activated in various tumors and cancer cells.^[@bib2],\ [@bib4],\ [@bib5],\ [@bib6],\ [@bib20],\ [@bib21]^ It was also reported that the expression of *BORIS* is predominantly controlled by DNA methylation^[@bib1]^ and that BORIS mediates the epigenetic regulation of other genes (*NY-ESO-1*, *NOTCH3*, *hTERT* and so on) in cancer cells.^[@bib8],\ [@bib22],\ [@bib23]^ In our previous study, however, no correlation between methylation status and *BORIS* gene expression was detected in tissues from gastric cancer.^[@bib6]^ Similar data were obtained in this work based on analysis of tissues from lung cancer. Based on these results, we suggest that the expression of *BORIS* is regulated by more complex epigenetic mechanisms.

To elucidate the regulation of *BORIS* beyond DNA methylation, we physically characterized the entire *BORIS* locus. A CpG island (−1096 to −762 from the first ATG codon) and two minisatellites (variable number of tandem repeats; *BORIS*-MS1 and *BORIS*-MS2) were identified through the characterization of the genomic DNA sequence upstream of the gene.^[@bib12]^ In this study, we examined the \~5.5-kb region upstream of the start codon of *BORIS.* A set of luciferase reporter cassettes carrying fragments from the upstream region of various sizes were constructed and tested ([Figure 2](#fig2){ref-type="fig"}). The highest luciferase activity was detected with a 700-bp promoter fragment (−1108/−425, p700) which contained CpG islands, a GATA-1 site and CCAAT box regions. This finding is in agreement with a previous study,^[@bib11]^ where three transcription start sites were mapped within the same 5′-upstream region. However, our analysis revealed a potential suppressor between −2909 and −1108 nt of the *BORIS* 5′-regulatory region containing the minisatellite region of *BORIS*--MS2 ([Figure 2b](#fig2){ref-type="fig"}). This finding suggests that the transcriptional regulation of *BORIS* is more complicated and that other types of regulation may exist in addition to DNA methylation. Moreover, there are also several reports indicating that minisatellite polymorphisms can influence gene expression.^[@bib16],\ [@bib17],\ [@bib24],\ [@bib25],\ [@bib26],\ [@bib27],\ [@bib28]^

In separate experiments, we investigated how polymorphic variants of *BORIS*--MS2 minisatellite affect the transcriptional activity of *BORIS* in cell lines using a luciferase reporter system ([Figure 4](#fig4){ref-type="fig"}). In 293T normal cell lines, all seven minisatellite constructs (TR10, 13, 14, 15, 16, 17 and 18) significantly decreased (5--10 times reduction) the activity of the p700 *BORIS* promoter, but there was no clear relationship between the tandem repeat copy number and level of gene expression. In principle, this result may be suggestive of the restriction of *in vivo* experiments. However, when the same constructs were transfected in lung cancer cells (H1299) or breast cancer cells (MDA-MB-231), the promoter activity was reduced only approximately two times compared with the control. This result suggests that the expression cassettes carrying *BORIS*--MS2 are controlled in a different way in normal and cancer cell lines. Similar results for transcriptional regulation by minisatellite fragments were previously reported with *H-Ras*, IL-1α, *IGF2*, *MUC6* and *TERT* genes.^[@bib16],\ [@bib17],\ [@bib24],\ [@bib25],\ [@bib26]^ Minisatellites of IL-1α, *MUC6* and *TERT* may control gene expression in cancer cell lines, although these are located in the intronic regions of genes.^[@bib16],\ [@bib17]^ We suggest that *BORIS*--MS2, located in the promoter region, differentially regulates the gene transcription in cancer cells and normal cells. This suggests a potential association between *BORIS*-MS2 and cancer. For example, specific alleles of *BORIS*-MS2 may affect susceptibility to lung cancer. In this study, we found a significantly elevated frequency of rare alleles of the minisatellite in lung cancer cases compared with cancer-free controls. In addition, short rare minisatellite alleles were associated with higher susceptibility in lung cancer patients. A similar result has been shown in a report examining the relationship between short rare alleles of *BORIS*-MS2 and breast cancer in a younger group.^[@bib12]^ Other studies on genetic susceptibility due to specific minisatellites have also been reported.^[@bib17],\ [@bib29],\ [@bib30],\ [@bib31]^

It is commonly accepted that genomic instability has a crucial role in the accumulation of genetic alterations that are responsible for cancer cell development.^[@bib32]^ It has also been reported that genomic instability in minisatellite regions is related to loss of heterozygosity and rearrangements in cancer tissues.^[@bib33],\ [@bib34]^ Thus, the *BORIS*-MS2 minisatellites may be involved in tumorigenesis not only via gene regulation but also via genomic instability. Further analysis is required to elucidate the correlation between rare minisatellite alleles and the susceptibility to lung cancer observed in this study.
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![Gene expression and methylation status of the 5′ flanking non-coding region of *BORIS*. (**a**) Gene expression of *BORIS* in tumor tissues (T1--T10) of lung cancer patients. (**b**) Results of bisulfite sequencing analysis of a CpG island in the 5′ flanking region of *BORIS* in tumor tissues (T) and lung cancer cells (H1299 cells and H1299 cells treated with 1 and 5 μ[M]{.smallcaps} 5-azad-C). Open circles (○) indicate non-methylated CpG; filled circles (•) indicate methylated CpG; percentages indicate the ratio of methylation.](emm201650f1){#fig1}

![Activity analysis of the *BORIS* promoter. (**a**) Structure of the \~6-kb upstream region of *BORIS*. The figure in the box shows the putative binding sites for TATA and GATA-1, the minisatellite region (*BORIS*-MS2) and the CpG islands. The position of the CCAAT box is shown in the figure. The results of the luciferase assay with the empty control vector and the *BORIS* promoter vectors with four different regions are shown on the right. (**b**) Expression of *BORIS* promoter-luciferase reporters. The upper boxed panel shows the positions of *BORIS*-MS2, the CpG islands and the putative binding sites for GATA-1 in the p2914 vector, which represents the highest expression level in the above study. The structures of the *BORIS* luciferase reporter vectors are shown on the left. The results of the luciferase assay are shown on the right. Firefly luciferase activities of at least four independent experiments were calculated after normalization to *Renilla* luciferase values.](emm201650f2){#fig2}

![Analysis of the core promoter of *BORIS*. (**a**) The upper panel shows the positions of putative binding sites for GATA-1 and the CCAAT box in the p700 vector, which had the highest expression in [Figure 2b](#fig2){ref-type="fig"}. This region represents the difference between the p678 and p700 vectors. The wild-type construct (p700) contained putative binding sites for GATA-1 and the CCAAT box, whereas the mutant constructs (GATA-1Δ\#1, GATA-1Δ\#2 and CCAATΔ) were mutated at the GATA-1 site or the CCAAT box in the p700 vector. (**b**) Luciferase activity of each vector is shown in the upper panel. The lower table shows the relative luciferase activity compared with control vector as the mean±s.e. and the *P*-values of at least four independent experiments.](emm201650f3){#fig3}

![Effect of allelic types of *BORIS*-MS2 in *BORIS* promoter luciferase constructs. (**a**) The structures of the p700 (\#1) and TR (*BORIS*-MS2) reporter constructs. The gray square indicates the *BORIS* p700 promoter region, and the open square represents the open reading frame of luciferase. The black squares include the *BORIS*-MS2 polymorphic regions; seven different sizes of *BORIS*-MS2 (10--18 copies) were inserted in the p700 plasmid. (**b**) The effects of *BORIS*-MS2 on gene expression in the luciferase reporter system. Three different cell lines (293T, H1299 and MDA-MB-231) were transfected with eight different vectors. (**c**) The table shows the relative luciferase activity compared with the p700 vector as the mean±s.e. and the *P*-values of four independent experiments.](emm201650f4){#fig4}

![Haplotyping of *BORIS*-MS2 in cancer-free controls and lung cancer patients. (**a**) Electrophoretic patterns of PCR products of *BORIS*-MS2 in controls. Seven *BORIS*-MS2 alleles and 12 haplotype patterns were detected in DNA from 590 cancer-free female controls. (**b**) Electrophoretic patterns of PCR products of *BORIS*-MS2 in lung cancer patients. Six *BORIS*-MS2 alleles and 10 haplotype patterns were detected in the DNA from 206 patients with lung cancer. The first and last lanes correspond to a 100-bp (M1; Invitrogen) and a 1-kb size marker (M2; Invitrogen). (**c**) Allelic genotypes and frequency in controls and cases with lung cancer. Bold numbers represent the rare alleles of *BORIS*-MS2. \**P*\<0.05.](emm201650f5){#fig5}

###### Age and sex distribution of cases and controls

                  *Controls,* N *(%)*   *Lung cancer cases,* N *(%)*                                        
  --------------- --------------------- ------------------------------ ------------ ----------- ----------- -----------
  *Age (years)*                                                                                             
   30--39         7 (2.1)               21 (8.0)                       28 (4.7)     2 (1.2)     2 (5.7)     4 (1.9)
   40--49         21 (6.4)              43 (16.3)                      64 (10.8)    10 (5.8)    4 (11.4)    14 (6.8)
   50--59         71 (21.8)             71 (26.9)                      142 (24.1)   37 (21.6)   7 (20.0)    44 (21.4)
   60--69         153 (46.9)            81 (30.7)                      234 (39.7)   84 (49.1)   11 (31.4)   95 (46.1)
   70--79         68 (20.9)             42 (15.9)                      110 (18.6)   34 (19.9)   9 (25.7)    43 (20.9)
   ⩾80            6 (1.8)               6 (2.3)                        12 (2.0)     4 (2.3)     2 (5.7)     6 (2.9)
                                                                                                            
  Average         62.9                  57.5                           60.5         63.4        61.1        63.0
  Median          64                    56                             62           64          64          64
  *N*             326                   264                            590          171         35          206

###### Comparison of allelic sizes and frequency of *Boris*--MS2

              *Controls,* N *(frequency)*   *Lung cancer cases,* N *(frequency)*                                                                               
  ---- ------ ----------------------------- -------------------------------------- ------------- ------------- ------------ ------------- -------------------- ---------
  10   785    1 (0.002)                     4 (0.008)                              5 (0.004)     1 (0.003)     1 (0.014)    2 (0.005)     1.15 (0.22--5.93)    0.871
  13   935    2 (0.003)                     4 (0.008)                              6 (0.005)     5 (0.015)     2 (0.029)    7 (0.017)     3.38 (1.13--10.12)   0.021\*
  14   990    392 (0.601)                   331 (0.627)                            723 (0.613)   219 (0.640)   47 (0.671)   266 (0.646)   1.15 (0.91--1.45)    0.236
  15   1050   250 (0.383)                   187 (0.354)                            437 (0.370)   113 (0.330)   19 (0.271)   132 (0.320)   0.80 (0.63--1.01)    0.069
  16   1100   2 (0.003)                     1 (0.002)                              3 (0.003)     3 (0.009)     ---          3 (0.007)     2.88 (0.58--14.31)   0.177
  17   1160   1 (0.002)                     ---                                    1 (0.001)     ---           ---          ---           ---                  0.554
  18   1220   4 (0.006)                     1 (0.002)                              5 (0.004)     1 (0.003)     1 (0.014)    2 (0.005)     1.15 (0.22--5.93)    0.871

Abbreviations: CI, confidence interval; OR, odds ratio; TR, tandem repeat. \**P*\<0.05.

###### The frequency of rare *Boris*-MS2 alleles in controls and lung cancer cases

                                   *Common alleles*   *Rare alleles*                                                                     
  --------------------- ---------- ------------------ ---------------- ------------- --- --- --- --- --- ---------- -------------------- ---------
  *Controls*                                                                                                                             
   Male                 652 (%)    392 (60.1)         250 (38.4)       642 (98.5)    1   2   2   1   4   10 (1.5)   1 (reference)           ---
   Female               528 (%)    331 (62.7)         187 (35.4)       518 (98.1)    4   4   1   0   1   10 (1.9)   1 (reference)           ---
   Total                1180 (%)   723 (61.3)         437 (37.0)       1160 (98.3)   5   6   3   1   5   20 (1.7)   1 (reference)             
                                                                                                                                         
  *Lung cancer cases*                                                                                                                    
   Male                 342 (%)    219 (64.0)         113 (33.0)       332 (97.0)    1   5   3   0   1   10 (3.0)   1.93 (0.80--4.69)      0.138
   Female               70 (%)     47 (67.2)          19 (27.1)        66 (94.3)     1   2   0   0   1   4 (5.7)    3.14 (0.96--10.29)    0.047\*
   Total                412 (%)    266 (64.6)         132 (32.0)       398 (96.6)    2   7   3   0   2   14 (3.4)   2.04 (1.02--4.08)     0.039\*

Abbreviations: CI, confidence interval; OR, odds ratio. \**P*\<0.05.

###### The frequency of short rare *Boris*-MS2 alleles in controls and lung cancer cases

                                   *Common+long rare alleles*   *Short rare alleles*                                                                                       
  --------------------- ---------- ---------------------------- ---------------------- --------- --------- --------- ------------- --- --- ---------- -------------------- ---------
  *Controls*                                                                                                                                                               
   Male                 652 (%)    392 (60.1)                   250 (38.3)             2 (0.3)   1 (0.2)   4 (0.6)   649 (99.5)    1   2   3 (0.5)    1 (reference)           ---
   Female               528 (%)    331 (62.7)                   187 (35.4)             1 (0.2)   0 (0.0)   1 (0.2)   520 (98.5)    4   4   8 (1.5)    1 (reference)           ---
   Total                1180 (%)   723 (61.3)                   437 (37.0)             3 (0.3)   1 (0.1)   5 (0.4)   1169 (99.1)   5   6   11 (0.9)   1 (reference)             
                                                                                                                                                                           
  *Lung cancer cases*                                                                                                                                                      
   Male                 342 (%)    219 (64.0)                   113 (33.0)             3 (0.9)   0 (0.0)   1 (0.3)   336 (98.2)    1   5   6 (1.8)    3.86 (0.96--15.54)    0.041\*
   Female               70 (%)     47 (67.2)                    19 (27.1)              0 (0.0)   0 (0.0)   1 (1.4)   67 (95.7)     1   2   3 (4.3)    2.91 (0.75--11.24)     0.105
   Total                412 (%)    266 (64.6)                   132 (32.0)             3 (0.7)   0 (0.0)   2 (0.5)   403 (97.8)    2   7   9 (2.2)    2.37 (0.98--5.77)     0.049\*

Abbreviations: CI, confidence interval; OR, odds ratio. \**P*\<0.05.

[^1]: These authors contributed equally to this work.
